Etizolam withdrawal is a benzodiazepine-type withdrawal, and it can become dangerous, especially after heavy or long use or when it is stopped abruptly. The safest way through it is a medically supervised setting where staff can watch symptoms, treat them and respond if something turns serious. If you or someone you love is taking etizolam daily and wants to stop, do not quit alone. Call a medical provider or a detox program first. If seizures, confusion, hallucinations or loss of consciousness occur, call 911.
This guide is written for families, for people who are thinking about detox, for people who also live with anxiety, depression or another mental health condition, and for legal professionals arranging court-directed care. It explains what etizolam is, why withdrawal happens, what it looks like, which signs are emergencies and what a supervised detox involves.
TL;DR
- Etizolam acts on the brain much like a benzodiazepine, so regular use can cause physical dependence, and stopping can cause withdrawal.
- Reported symptoms range from anxiety, insomnia, tremor and a racing heart to hallucinations and seizures in severe cases.
- Stopping suddenly is risky. Seizures, psychosis and confusion are documented after rapid discontinuation of etizolam.
- Medically supervised detox lets clinicians monitor symptoms on a schedule and adjust treatment as they change.
- Etizolam is easy to miss: it does not appear on the standard urine drug screen used in many U.S. outpatient clinics, so families should say plainly what was taken.
Table of Contents
- What etizolam is and why it causes withdrawal
- How quickly dependence can develop
- Symptoms of etizolam withdrawal
- How long does etizolam withdrawal last?
- Why stopping suddenly is risky
- What medically supervised detox involves
- When etizolam goes unnoticed
- When anxiety, depression or another condition is also present
- Court-directed treatment and etizolam
- Our perspective
- Getting help at Sylmar Treatment Center
- FAQ
- Sources
What etizolam is and why it causes withdrawal
Etizolam is a thienotriazolodiazepine. In plain terms, it is a drug related to benzodiazepines such as diazepam (Valium). A 2022 case report describes it as a full agonist at the GABA-A receptor, the brain’s main calming pathway, with pharmacology similar to diazepam but 5 to 10 times more potent. The same report notes it is approved for anxiety in Japan, Italy and India but not approved for medical use in the United States. In the U.S., people usually encounter it as a pill or powder bought online or on the street, often sold as a counterfeit or “research” product.
When the brain is repeatedly flooded with a calming drug, it adapts by turning its own activity up. Take the drug away and that overactivity is left with nothing to balance it. That rebound is withdrawal. It is the same mechanism behind withdrawal from prescribed benzodiazepines, which is why the World Health Organization’s Expert Committee on Drug Dependence concluded that etizolam’s effects are very similar to Schedule IV benzodiazepines and that it can produce dependence. The committee’s critical review also found that non-medical use is associated with tolerance, craving and withdrawal when use stops.
Some animal research suggests etizolam may cause tolerance less readily than lorazepam. Human dependence, however, is documented in the same WHO review, and clinicians treat it as seriously as dependence on other benzodiazepines.

How quickly dependence can develop
Many people assume dependence takes years. It can take far less. A 2014 case report from India described a 23-year-old man whose etizolam use climbed from 0.25 mg a day to 2.5 mg a day over about one month. He developed palpitations, tremulousness, poor sleep, agitation when his dose dropped, and craving, and he met five of six ICD-10 dependence criteria. A factsheet from the British Columbia Centre on Substance Use likewise states that dependence and withdrawal may occur in under four weeks.
Two things make this easy to underestimate. First, etizolam is short-acting. Its oral effects start within roughly 30 to 60 minutes, peak at 3 to 4 hours and last about 6 to 8 hours, so people tend to redose several times a day, and each gap between doses can bring mini-withdrawals. Second, reported half-lives vary widely, from 3.4 hours in early studies to 12 to 14 hours in later reports, which is one reason the timing of withdrawal is hard to predict for any one person.
Symptoms of etizolam withdrawal
Symptoms depend on how much was taken, for how long, whether other substances were involved and the person’s own health. Reports in the medical literature describe:
- Anxiety, irritability and agitation, often worse than the anxiety that led the person to use in the first place.
- Sleep problems, from poor sleep to severe insomnia.
- Physical symptoms: tremor, sweating, headache, dizziness, tinnitus (ringing in the ears), nausea, vomiting, loss of appetite and weakness.
- Heart and blood pressure changes: palpitations, a fast pulse and a drop in blood pressure on standing. These are listed in the British Columbia factsheet.
- Craving for the drug, which can push a person back to using just to end the discomfort.
A 2023 case report shows how heavy use can look. A patient taking 20 to 30 mg of etizolam a day, estimated at 100 to 150 mg of diazepam equivalent, developed withdrawal signs the day after admission: dilated pupils, shivering, insomnia, diarrhea, muscle pain, anxiety, irritability, tingling and numbness, and auditory and visual hallucinations. His team managed him with a long-acting benzodiazepine taper, gabapentin and supportive medicines, and he was discharged on day 6 to continue a longer outpatient taper.
That last detail matters for families. Even when the acute phase is brought under control in days, tapering and recovery can continue for weeks or longer. Our article on the benzodiazepine detox timeline explains why some people have symptoms that linger after the acute phase.
How long does etizolam withdrawal last?
No source gives one reliable timeline, and anyone who promises one is guessing. What the evidence supports is a range of patterns:
- Because etizolam is short-acting, symptoms can begin soon after the last dose rather than days later. In the 2023 case above, signs appeared the day after admission.
- The acute, highest-risk phase is typically measured in days. The cases above ended with hospital discharge on day 5 and day 6.
- A gradual taper afterward can run much longer, and lingering anxiety and sleep trouble can follow.
The length depends on dose, duration, other drugs in the picture and any underlying anxiety or mood disorder. That is why a clinician’s assessment, not a calendar, should set the plan.
Why stopping suddenly is risky
The most serious risk of abrupt discontinuation is a withdrawal seizure. A 2018 case report notes that rapid discontinuation of etizolam can lead to a benzodiazepine withdrawal syndrome with hallucinations, psychosis and seizures. A separate case report documented a patient who stopped etizolam abruptly out of fear of dependence and presented with a seizure-related emergency in the week that followed. Another published case described etizolam withdrawal catatonia, a state of severe motor and behavioral disturbance.
Severe complications are described as rare, and they are more likely after high doses. The British Columbia drug information sheet lists seizures, psychosis, agitation, confusion and hallucinations as possible outcomes of severe withdrawal. But nobody can tell in advance whether a particular person will be one of the rare cases, and etizolam bought online rarely has a reliable dose. That uncertainty is the reason to plan for supervision rather than hope.
Signs that mean call 911
Call 911 or go to the nearest emergency department if the person has:
- a seizure or convulsions;
- hallucinations, or seeing or hearing things that are not there;
- severe confusion, or not knowing where they are;
- extreme agitation or aggression;
- a very fast or irregular heartbeat, fainting or chest pain;
- unresponsiveness or trouble waking, especially if other sedatives, alcohol or opioids were also taken.
Seizures from sedative withdrawal are treated as emergencies. The 2024 ASAM/AAAP guideline recommends benzodiazepines as first-line treatment for sedative-related seizures, with phenobarbital or propofol considered if seizures do not respond. That is hospital-level care, not something to manage at home.
What medically supervised detox involves
Medically supervised detox means clinicians assess you, monitor you through withdrawal and treat symptoms as they appear, in a setting built to respond if something changes. Published case reports show what that looks like in practice.
In a 2022 U.S. case report, a man who had taken about 40 mg a day of internet-purchased etizolam for eight months was admitted for supervised withdrawal. Staff tracked his symptoms with the CIWA scale, a standard checklist that scores withdrawal severity, and guided oral lorazepam doses by those scores. His course was uncomplicated and he went home on day 5, after which his prescriber adjusted his non-benzodiazepine anxiety medications.
The general standard for monitoring is set out by ASAM, the American Society of Addiction Medicine. Its withdrawal management guideline says patients with moderate to severe withdrawal, or who need medication, should be reassessed every 1 to 4 hours for the first 24 hours, and monitoring can be spaced to every 4 to 8 hours once symptoms stabilize, for example a CIWA-Ar score under 10. A person at home cannot do that kind of scheduled reassessment.

Who most needs a supervised setting
A 2015 review of sedative misuse states that sedative withdrawal is most safely managed as an inpatient when the person:
- has used high doses;
- has a history of seizures or delirium tremens (the severe, confused state seen in serious alcohol withdrawal);
- has unstable medical or psychiatric problems.
The same review explains that people coming off short-acting sedatives may do better when clinicians substitute a long-acting one, with phenobarbital as an option for acute withdrawal. Etizolam is short-acting, which is another reason decisions about medication belong to a prescribing clinician. Our guide to examples of detox treatment protocols and the family guide to the medically supervised detox process walk through what the days look like.
When etizolam goes unnoticed
Etizolam is one of the designer benzodiazepines, drugs that are not approved for any medical use by the FDA. UpToDate’s benzodiazepine poisoning chapter, updated in August 2025, states that misuse of these drugs, explicitly naming etizolam and bromazolam, is increasingly recognized.
The practical problem is detection. The 2022 U.S. case report found that etizolam is not picked up by the standard urine drug screen at U.S. outpatient clinics, so a person in long-term recovery from other drugs can develop a quiet etizolam addiction that no routine test flags. Detection windows also differ by drug: how long benzodiazepines stay in urine varies from one compound to another, and a negative screen does not rule out a designer product.
For families, the lesson is to tell the care team everything you know. Mention pills or powders bought online, the brand or label if there is one, the daily amount if known, how long it has gone on, and any alcohol, opioids or other sedatives. If you see packaging, keep it. Related designer drugs bring similar risks: see our articles on bromazolam withdrawal and designer benzodiazepine withdrawal.
When anxiety, depression or another condition is also present
Many people start etizolam to quiet anxiety or sleeplessness. When they stop, the original anxiety returns and often feels louder, mixed with withdrawal symptoms. Telling the two apart takes a clinician who can assess both. The 2014 Gupta and Garg report argues that treatment options once dependence develops include treating the primary disorder, switching to a longer-acting benzodiazepine, SSRIs and psychotherapy, which shows why substance use and mental health are treated together rather than in sequence.
If a person also has depression, trauma, bipolar disorder or other conditions, or has used several substances, the case for a program that treats both at once is strong. Our dual diagnosis program is built for that overlap.
Court-directed treatment and etizolam
Legal professionals sometimes need to place a client in treatment on a court’s timetable. Withdrawal from a sedative is a medical event, so the first question is whether the person can safely detox before any program begins. A placement that starts with a medical assessment and supervised detox protects both the client and the case plan. We take court-directed placements and can explain how admission works for your client; see our programs page.
Our perspective
Etizolam catches families off guard. It is not prescribed here, it does not show on many routine drug tests, and the person taking it often looks like they are managing their anxiety until the day the supply runs out.
We believe the right response is a calm, careful, medical one. At Sylmar Treatment Center we are a six-bed residential facility, and that size shapes how we work: a small group means staff know each person, and comprehensive assessments lead to custom care plans rather than a standard template.
Withdrawal from a sedative and the anxiety or mood problem underneath it are not separate stories. We treat substance use and co-occurring mental health conditions together, with medication management under psychiatric oversight, so the person is not left to sort out which symptom is which.
We hold a California DHCS license and Joint Commission accreditation, and our admissions line is staffed 24/7, because withdrawal decisions rarely happen at convenient hours. If you are unsure whether what you are seeing is serious, call us and describe it plainly.
Jim
Getting help at Sylmar Treatment Center
If you or a family member is dependent on etizolam, our medical detoxification program provides medically supervised withdrawal in a six-bed licensed and accredited facility. After detox, residential treatment and behavioral rehabilitation continue the work, with individualized plans shaped by a comprehensive assessment. We also offer recovery support for 7-OH and other emerging substances.

Admissions support is available 24/7 through our website. When you call, have the substance, the approximate daily amount, how long it has been used and any other drugs or medical conditions ready. If the person is having a seizure, hallucinating or cannot be woken, call 911 first.
FAQ
Is it safe to stop etizolam suddenly?
No. Abrupt discontinuation can cause a benzodiazepine-type withdrawal syndrome with hallucinations, psychosis and seizures, according to published case reports. Risk rises with higher doses and longer use. Speak with a medical provider or a detox program before stopping, and call 911 for any seizure.
How long does etizolam withdrawal last?
It varies. Published cases show acute withdrawal managed over roughly five to six days in a hospital, with a longer taper afterward for heavy use. Dose, duration and other substances all change the course, so a clinician’s assessment should guide the plan.
Can a standard drug test detect etizolam?
Not necessarily. A 2022 U.S. case report found etizolam is not detected on the standard urine drug screen available at U.S. outpatient clinics. If etizolam use is suspected, tell the care team directly rather than relying on a test result.
Is etizolam legal or approved in the United States?
Etizolam is not approved for medical use in the United States, according to a 2022 case report. It is approved for anxiety in Japan, Italy and India. Because it is sold outside regulated channels, the actual dose in any tablet or powder can be unknown.
Sources
- Etizolam, WHO Expert Committee on Drug Dependence
- Etizolam Critical Review Report, WHO ECDD (2019)
- Etizolam Use Disorder and Withdrawal, 2022 case report
- A case of etizolam dependence, PMC (2014)
- Etizolam in British Columbia’s Illicit Drug Market, factsheet
- Etizolam information sheet, British Columbia Centre on Substance Use
- Treatment of concurrent etizolam and tianeptine withdrawal, PMC (2023)
- Novel psychoactive substances: overdose of 3-FPM and etizolam, PMC (2018)
- ASAM/AAAP Clinical Practice Guideline on Stimulant Use Disorder, PMC (2024)
- ASAM withdrawal management guideline (2020)
- Prescription Sedative Misuse and Abuse, PMC (2015)
- Benzodiazepine poisoning, UpToDate (updated August 2025)

